Treatment of Epstein-Barr Virus infection in immunocompromised patients.
Pociupany M, Snoeck R, Dierickx D, Andrei G.
Biochem Pharmacol. 2024 Jul;225:116270. doi: 10.1016/j.bcp.2024.116270. Epub 2024 May 10.
Infectious Mononucleosis.
Dunmire SK, Hogquist KA, Balfour HH.
Curr Top Microbiol Immunol. 2015;390(Pt 1):211-40. doi: 10.1007/978-3-319-22822-8_9.
Epstein-Barr Virus and Systemic Autoimmune Diseases.
Houen G, Trier NH.
Front Immunol. 2021 Jan 7;11:587380. doi: 10.3389/fimmu.2020.587380. eCollection 2020.
Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR.
J Clin Pathol. 2019 Oct;72(10):651-658. doi: 10.1136/jclinpath-2019-205822. Epub 2019 Jul 17.
Virological Markers in Epstein-Barr Virus-Associated Diseases.
Lupo J, Truffot A, Andreani J, Habib M, Epaulard O, Morand P, Germi R.
Viruses. 2023 Feb 28;15(3):656. doi: 10.3390/v15030656.
[EB virus infection].
Kawa K.
Nihon Rinsho Meneki Gakkai Kaishi. 1996 Dec;19(6):583-7.
Asymptomatic infection with EB virus.
Sutton RN, Marston SD, Almond EJ, Reynolds K, Pounds FJ.
J Clin Pathol. 1974 Feb;27(2):97-100. doi: 10.1136/jcp.27.2.97.
[EB virus].
Oonishi A, Kariyama K.
Nihon Rinsho. 2015 Dec;73 Suppl 9:654-7.
[A case of facial diplegia due to EB virus infection].
Matsushima K, Shinohara Y, Yamamoto M.
Rinsho Shinkeigaku. 1990 Sep;30(9):1013-6.
Cell-mediated immune responses in man to Epstein-Barr (EB) virus infection.
Lai PK, Alpers MP.
Comp Immunol Microbiol Infect Dis. 1979;2(4):565-85. doi: 10.1016/0147-9571(79)90099-7.
